Supplementary Material: Efficacy of Nivolumab Plus Ipilimumab in Advanced HCC

145 patients from an international multicenter retrospective study were analyzed to assess the real-world efficacy and safety of nivolumab plus ipilimumab in advanced hepatocellular carcinoma. The dataset compares outcomes for 44 high-risk patients (with ≥50% liver involvement, Vp4 portal vein tumor thrombosis, or bile duct invasion) against 101 non-high-risk patients. It includes data on objective response rates, progression-free survival, overall survival, and adverse events from six hospitals in Korea, Hong Kong, Singapore, and Taiwan.

Use Cases

• Comparing treatment efficacy (ORR, PFS, OS) between high-risk and non-high-risk HCC patient groups.
• Analyzing the association between specific high-risk features (≥50% liver involvement, Vp4 PVTT, bile duct invasion) and survival outcomes.
• Investigating adverse event profiles, particularly hyperbilirubinemia, in patients receiving nivolumab plus ipilimumab.
• Conducting multivariable analysis to identify independent predictors of shorter progression-free and overall survival.

Strengths

• Contains detailed clinical outcome data for 145 patients from an international, multicenter study.
• Focuses on a specific high-risk population (≥50% liver involvement, Vp4 PVTT, bile duct invasion) often excluded from major clinical trials.
• Provides real-world data spanning 2016 to 2024 from hospitals in Korea, Hong Kong, Singapore, and Taiwan.

Limitations

• The exact column names and row count are not provided in the metadata, limiting precise understanding of the dataset's structure.
• The dataset is derived from a retrospective study, which may have inherent biases compared to prospective trials.
• Patient selection excluded those with Child-Pugh B/C liver function or ECOG > 2, limiting generalizability to the entire advanced HCC population.

Provenance

Source

figshare admin karger

Collection Method

International, multicenter retrospective study conducted at six hospitals.

Time Range

2016 to 2024

Freshness

Last updated on 2026-03-21.

Geography

Korea, Hong Kong, Singapore, Taiwan